Concepedia

Publication | Closed Access

LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis

DOI

19

Citations

0

References

2012

Year

Ed Keystone, Peter C. Taylor, Mark C. Genovese, D. Schlichting, Scott D. Beattie, C. Gaich, R. Fidelus Gort, Monica Luchi, WL Macias
Annals of the Rheumatic Diseases

No additional data available for this publication yet. Check back later!